MYC phosphorylation at novel regulatory regions suppresses transforming activity

Cancer Research

Volumn 73, Issue 21, 2013, Pages 6504-6515

  Wasylishen, Amanda R ^a,b   Chan Seng Yue, Michelle ^c   Bros, Christina ^b   Dingar, Dharmendra ^b   Tu, William B ^a,b   Kalkat, Manpreet ^a,b   Chan, Pak Kei ^b   Mullen, Peter J ^b   Huang, Ling ^b   Meyer, Natalie ^a,b   Raught, Brian ^a,b   Boutros, Paul C ^a,c   Penn, Linda Z ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MUTANT PROTEIN; MYC PROTEIN; ONCOPROTEIN;

ACINAR CELL; ALLELE; ARTICLE; BREAST EPITHELIUM; CELL ADHESION; CELL GROWTH; CELL STRAIN; CELL STRAIN MCF10A; CELL TRANSFORMATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; MUTANT; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; COLONY-FORMING UNITS ASSAY; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, HUMAN; MUTATION; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXYGEN CONSUMPTION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REGULATORY SEQUENCES, NUCLEIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84887183079     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4063     Document Type: Article

References (40)

1. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8: 976-90.
2. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904-17.
3. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153: 320-34.
4. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-83.
5. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 2013;27: 504-13.
6. Hann SR. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity, and biological function. Semin Cancer Biol 2006;16: 288-302.
7. Thomas LR, Tansey WP. Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res 2011;110: 77-106.
8. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 2004;3: 1133-7.
9. Chang DW, Claassen GF, Hann SR, Cole MD. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 2000;20: 4309-19.
10. Conzen SD, Gottlob K, Kandel ES, Khanduri P, Wagner AJ, O'Leary M, et al. Induction of cell-cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. Mol Cell Biol 2000;20: 6008-18.
11. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon- Cardo C, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436: 807-11.
12. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011;71: 925-36.
13. Wasylishen AR, Stojanova A, Oliveri S, Rust AC, Schimmer AD, Penn LZ. New model systems provide insights into Myc-induced transformation. Oncogene 2011;30: 3727-34.
14. Hollern DP, Yuwanita I, Andrechek ER. A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer. Oncogene 2013;32: 1296-304.
15. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994;14: 5510-22.
16. Lutterbach B, Hann SR. Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation. Oncogene 1997;14: 967-75.
17. Luscher B, Kuenzel EA, Krebs EG, Eisenman RN. Myc oncoproteins are phosphorylated by casein kinase II. EMBO J 1989;8: 1111-9.
18. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 1999;274: 32580-7.
19. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-68.
20. Ponzielli R, Boutros PC, Katz S, Stojanova A, Hanley AP, Khosravi F, et al. Optimization of experimental design parameters for highthroughput chromatin immunoprecipitation studies. Nucleic Acids Res 2008;36:e144.
21. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A 2009;106: 480-5.
22. Schweiger R, Linial M. Cooperativity within proximal phosphorylation sites is revealed from large-scale proteomics data. Biol Direct 2010;5: 6.
23. Goldenberg NM, Steinberg BE. Surface charge: a key determinant of protein localization and function. Cancer Res 2010;70: 1277-80.
24. Chen RQ, Yang QK, Lu BW, Yi W, Cantin G, Chen YL, et al. CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 2009;69: 2663-8.
25. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, et al.Aquantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 2008;105: 10762-7.
26. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitinmediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999;18: 717-26.
27. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14: 2501-14.
28. Thibodeaux CA, Liu X, Disbrow GL, Zhang Y, Rone JD, Haddad BR, et al. Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant. Breast Cancer Res Treat 2009; 116: 281-94.
29. Huang Z, Traugh JA, Bishop JM. Negative control of the Myc protein by the stress-responsive kinase Pak2. Mol Cell Biol 2004;24: 1582-94.
30. Simpson DR, Yu M, Zheng S, Zhao Z, Muthuswamy SK, Tansey WP. Epithelial cell organization suppresses Myc function by attenuating Myc expression. Cancer Res 2011;71: 3822-30.
31. Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474: 609-15.
32. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490: 61-70.
33. Hammerman PS, Lawrence MS, Voet D, Jing R, Cibulsakis L, Sivanchenko A, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489: 519-25.
34. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497: 67-73.
35. Rabbitts TH, Hamlyn PH, Baer R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 1983;306: 760-5.
36. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5: 56-61.
37. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, Magrath I. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood 1994;84: 883-8.
38. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006;281: 34725-9.
39. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007;9: 765-74.
40. Wasylishen AR, Kalkat M, Kim SS, Pandyra A, Chan PK, Oliveri S, et al. MYC activity is negatively regulated by a C-terminal lysine cluster. Oncogene. 2013 Feb 25. [Epub ahead of print].